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Hypofractionation for prostate cancer: tested and proven
In The Lancet Oncology, results of two randomised 
phase 3 trials of hypofractionation—ie, fewer, larger, 
daily fractions of radiotherapeutic treatment—for 
prostate cancer are reported.1,2 In the ﬁ nal results from 
the Conventional or Hypofractionated High-dose 
Intensity Modulated Radiotherapy in Prostate Cancer 
(CHHiP) trial, David Dearnaley and colleagues advocate 
for hypofractionation,1 whereas in the ﬁ nal results 
from the Hypofractionated Irradiation for Prostate 
cancer (HYPRO) trial, Luca Incrocci and colleagues 
recommend that hypofractionation not be adopted.2 
How can we explain this apparent discordance? 
The short explanation is that the two trials have 
diﬀ erent hypotheses.
What is the rationale for hypofractionation in 
prostate cancer? In 1999, Brenner and Hall claimed 
that the fractionation sensitivity of prostate cancer was 
such that “appropriately designed hypofractionation 
schemes would be expected to maintain current 
levels of tumor control and late sequelae...with the 
logistical and ﬁ nancial advantages of fewer numbers 
of fractions”.3 As a result, investigators across the globe 
designed prospective trials to test the hypofractionation 
hypothesis in prostate cancer. Trials took two forms 
depending on the nature of the hypothesis: a superiority 
design or a non-inferiority design.
Some investigators postulated that hypo-
fractionation would increase eﬃ  cacy compared with 
conventional fractionation, which in retrospect was 
an overinter pretation of Brenner and Hall’s paper. 
Hypo fractionation has not been proven superior 
to conventional fractionation in any superiority 
trial to date.4,5 HYPRO is the largest of the published 
superiority trials (n=804).2 The primary hypothesis 
was that hypofractionation (19 fractions of 
3·4 Gy, three fractions per week) would increase 
5-year relapse-free survival by 10%, from 70% to 
80%, compared with conventional fractionation 
(39 fractions of 2·0 Gy, ﬁ ve fractions per week). HYPRO 
enrolled men with intermediate-risk and high-risk 
disease, although most patients were high risk (>70%). 
After a median follow-up of 60 months (IQR 51–69), 
Incrocci and colleagues reported 5-year relapse-free 
survival of 80·5% (95% CI 75·7–84·4) in patients 
allocated hypofractionation and 77·1% (71·9–81·5) 
in individuals assigned conventional fractionation 
(adjusted hazard ratio [HR] 0·86, 95% CI 0·63–1·16; 
plogrank=0·36).2 Their conclusion is in keeping with all 
previous superiority trials; simply put, the evidence 
to date does not support the notion that moderately 
hypofractionated radiotherapy results in improved 
eﬃ  cacy. The increase in acute6 and late7 gastrointestinal 
and genitourinary toxic eﬀ ects recorded with the 
hypofractionation regimen used in HYPRO should 
temper enthusiasm for this fractionation schedule.
Other, perhaps more cautious, investigators designed 
trials with a non-inferiority hypothesis. Speciﬁ cally, these 
trials investigated whether moderately hypofractionated 
radiotherapy was not worse than conventionally 
fractionated radiotherapy regarding relapse-free survival. 
CHHiP is a large (n=3216), three-arm, non-inferiority 
trial comparing two hypofractionation regimens 
(60·0 Gy delivered as 20 fractions of 3·0 Gy, ﬁ ve fractions 
per week; and 57·0 Gy delivered as 19 fractions of 
3·0 Gy, ﬁ ve fractions per week) with a conventionally 
fractionated regimen (74·0 Gy as 37 fractions of 
2·0 Gy, ﬁ ve fractions per week).1 Most patients 
enrolled in CHHiP had low-risk or intermediate-risk 
disease, although 12% had high-risk disease. After a 
median follow-up of 62·4 months (IQR 53·9–77·0), 
5-year biochemical or clinical failure-free rates were 
90·6% (95% CI 88·5–92·3) in patients allocated the 
60·0 Gy hypofractionation schedule compared with 
85·9% (83·4–88·0) in those assigned the 57·0 Gy 
hypofractionation schedule and 88·3% (86·0–90·2) in 
those allocated conventional fractionation. The 
critical HR for non-inferiority was 1·208. The 60·0 Gy 
hypofractionation schedule was judged non-inferior to 
the conventional regimen of 74·0 Gy (HR 0·84, 
90% CI 0·68–1·03; pNI=0·0018); however, non-inferiority 
of the 57·0 Gy hypofractionation schedule could not 
be claimed (1·20, 0·99–1·46; pNI=0·48). Results of 
the non-inferiority NRG Oncology 0415 trial have 
also been reported.8 After a median follow-up of 
5·8 years, researchers concluded that hypofractionation 
(28 fractions of 2·5 Gy, ﬁ ve fractions per week) was 
non-inferior to conventional fractionation (41 fractions 
of 1·8 Gy, ﬁ ve fractions per week) in men with low-risk 
prostate cancer (HR for the primary endpoint of 5-year 
disease-free survival 0·85, 95% CI 0·64–1·14), which 
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met the predeﬁ ned non-inferiority criterion (critical 
HR <1·52). Findings of a large non-inferiority trial of 
1200 patients (PROFIT; NCT003046759), comparing 
60·0 Gy hypofractionation (the same regimen as in the 
CHHiP trial) with 78·0 Gy conventional fractionation are 
awaiting publication (Catton C, Princess Margaret Cancer 
Centre, personal communication).
It is noteworthy that the HRs for the primary endpoint 
in the NRG Oncology (0·85) and CHHiP (0·84) trials are 
similar. This consistency is noted despite the inclusion 
of patients with diﬀ erent risk groupings, varying 
durations of androgen suppression (ranging from none 
to 6 months), and diverse radiotherapy regimens. 
The fact that both studies report a HR below 1·0 should 
mitigate any concerns that hypofractionation is less 
eﬀ ective than conventional fractionation. These ﬁ ndings 
together should reassure skeptical practitioners that 
hypofractionation can be introduced without a decrease 
in eﬃ  cacy.
On the other hand, the ﬁ ndings of the non-inferiority 
studies are somewhat inconsistent with respect to 
toxic eﬀ ects. The CHHiP trial has reported extensive 
information relating to clinician-reported toxic eﬀ ects 
and patient-reported outcomes. Acute toxic eﬀ ects 
peaked sooner with hypofractionation compared 
with conventional fractionation, but no diﬀ erences in 
long-term toxic eﬀ ects or patient-reported outcomes9 
were reported. Researchers on the NRG Oncology trial also 
noted a slight increase in late grade 2 gastrointestinal and 
genitourinary toxic eﬀ ects, but no diﬀ erences in severe 
toxic eﬀ ects were recorded.8 The observation of increased 
late toxic eﬀ ects is perhaps not surprising, because the 
biological eﬀ ective dose of the hypofractionated regimen 
in NRG Oncology 0415 (128·0 Gy) is slightly greater 
than that of the hypofractionated regimen in CHHiP 
(120·0 Gy), assuming the α/β ratio of rectum and bladder 
to be 3·0 Gy.
To put these results into context, it is important 
to acknowledge that there are several other radio-
therapeutic approaches currently in use for men 
with low-risk and intermediate-risk prostate 
cancer, including brachytherapy (low-dose rate 
and high-dose rate), and active surveillance in 
selected patients. More germane is the use of 
extreme hypofractionation schedules or stereotactic 
body radiotherapy. Preliminary results of extreme 
hypofractionation schedules (four or ﬁ ve fractions of 
7·0–10·0 Gy) have been reported,10 but no data from 
randomised trials of stereotactic body radiotherapy 
have been published up to now. In one randomised 
trial (ISRCTN45905321), 39 fractions of 2·0 Gy were 
compared with seven fractions of 6·1 Gy. Although 
not technically stereotactic body radiotherapy, this 
trial is probably the closest comparison of extreme 
hypo fractionation with conventional fractionation 
that we will have in the short term. Evidence to support 
stereotactic body radiotherapy is growing but remains 
weak (in quality and quantity) compared with more 
moderate hypofractionation schedules. 
In view of these reports, should radiation oncologists 
routinely abandon conventional fractionation and move 
to hypofractionation? I do not think so; I agree with 
the HYPRO investigators that the hypofractionation 
regimen used in their study (19 fractions of 3·4 Gy) 
should not be adopted. On the other hand, the results 
from NRG Oncology 04158 and CHHiP1 suggest 
that hypofractionation will not result in any loss of 
eﬃ  cacy and could make treatment less expensive and 
more convenient for patients when compared with 
conventionally fractionated radiotherapy. The NRG 
Oncology trial investigators did note a slight increase 
in clinician-reported grade 2 gastrointestinal and 
genitourinary toxic eﬀ ects, and practitioners might use 
this ﬁ nding as justiﬁ cation not to adopt this particular 
hypofractionation schedule, particularly in patients 
with large prostates or clinically signiﬁ cant pre-existing 
urinary dysfunction. I expect that future ancillary analyses 
of the NRG Oncology study will deﬁ ne the appropriate 
dose constraints to keep grade 2 gastrointestinal and 
genitourinary toxic eﬀ ects low, as we learned with 
dose-escalation studies of conventional fractionation. 
Excess toxic eﬀ ects, however, were not recorded with 
60·0 Gy in 20 fractions in the CHHiP trial;1 the results of 
the PROFIT trial will provide more information on the 
4-week schedule. For practitioners interested in judicious 
use of resources and patients’ convenience, this regimen 
can be presented conﬁ dently and discussed with patients 
as an alternative to conventional fractionation. 
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Osteosarcoma is the most common malignant tumour 
of the bone but only ﬁ ve cytotoxic chemotherapy 
drugs—doxorubicin, cisplatin, and high dose 
methotrexate (MAP), and ifosfamide and etoposide—
have been shown to be of beneﬁ t. 10-year overall 
survival is about 60% and has not changed in more 
than 30 years.1 Consequently, it is imperative to explore 
the activity of novel agents in osteosarcoma with the 
goal of improving outcome and, ultimately, if outcome 
is suﬃ  ciently improved and a low-risk group can be 
identiﬁ ed, decreasing treatment-related morbidity. 
In The Lancet Oncology, Sophie Piperno-Neumann and 
colleagues2 present the results of OS2006, a randomised 
trial of zolendronate in addition to chemotherapy in 
newly diagnosed osteosarcoma. Unfortunately, the trial 
showed an absence of improvement in 3-year event-free 
survival in the zolendronate plus chemotherapy 
group (57·1% [95% CI 48·8–65·0]) compared with the 
chemotherapy alone group (63·4% [55·2–70·9], HR 1·36 
[95% CI 0·95–1·96]; p=0·094). In fact, trial enrolment 
was terminated prematurely for futility when an interim 
analysis found the likelihood of showing beneﬁ t to be 
almost null. 
Several important lessons can be learned from this and 
other recently completed phase 3 trials in osteosarcoma. 
This study was done as a collaboration of three clinical 
trials groups in France. Despite this cooperative approach 
and the so-called non-restrictive eligibility criteria, 7 years 
were required to accrue 318 patients. As a consequence 
of the non-restrictive eligibility, there was heterogeneity 
in the evaluable population; patients could have 
localised, possible, or deﬁ nite metastatic disease, axial 
or appendicular primary tumours, and metastatic sites 
restricted to the lung or in other sites. Although sensitivity 
analyses support the authors’ conclusion that a negative 
trial result is not due to imbalances in the randomised 
population, it is preferable for outcome analysis to be 
restricted to a homogeneous patient population.
Heterogeneity of the patient population and the 
duration needed to enrol a suﬃ  cient number of patients 
emphasise the importance of international collaboration 
for the undertaking of phase 3 trials in osteosarcoma. 
The EURAMOS-1 trial enrolled 2260 patients over 
6 years and outcome analyses were done in a 
homogenous patient population showing the feasibility 
of international cooperation in phase 3 trials of 
osteosarcoma.3,4 Unfortunately, EURAMOS-1, which 
tested the eﬀ ect on event-free survival of the addition of 
ifosfamide and etoposide to MAP in high-risk patients 
and the addition of interferon to MAP in low-risk 
patients, showed no beneﬁ t to either intervention.5
OS2006 and EURAMOS-1 show that a collaborative 
eﬀ ort and a 5–10 year time investment is required to 
do deﬁ nitive phase 3 trials in osteosarcoma. In view of 
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